Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892089 | 0.88 | ELANE (0.74) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL394572 | 0.84 | ELANE (0.71) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL395186 | 0.83 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL391816 | 0.83 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL2894531 | 0.80 | MAPT (0.72) | ELANECYP2C9MAPTHTTLMNA | |
| SCHEMBL14899950 | 0.80 | ELANE (0.67) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL2617947 | 0.79 | ELANE (0.72) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL8056317 | 0.78 | ELANE (0.65) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| Bay-678 SCHEMBL1245235 | 0.78 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| Bay-678 SCHEMBL1245297 | 0.78 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546113-B1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | BAYER IP GMBH (DE) | 2013-05-01 | — | — | EP | disclosed |
| EP-1546113-B1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | BAYER IP GMBH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687510-B2 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER HEALTHCARE AG (DE) | 2010-03-30 | — | — | US | disclosed |
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2004024700-A1 | PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES | BAYER HEALTHCARE AG (DE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160801-A1 | Pyrimidinone derivaties as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | PTGIS, PTGIR, FPR1 | ELANE 59/4885CYP2C9 4171/4885ADRB1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.